AstraZeneca Reports Imfinzi and Imjudo Improve Progression-Free Survival in Early Liver Cancer
AstraZeneca announced that its combination of Imfinzi and Imjudo, used alongside lenvatinib and transarterial chemoembolization (TACE), achieved a statistically significant improvement in progression-free survival in patients with early-stage, unresectable liver cancer. The results come from the Phase III EMERALD-3 trial, which also showed a positive trend toward improved overall survival compared to standard TACE treatment alone. This combination therapy represents a potential advancement in treating hepatocellular carcinoma, a common form of liver cancer where patients often experience disease progression within months. 
AstraZeneca Reports Imfinzi and Imjudo Improve Progression-Free Survival in Early Liver Cancer